Correlation Engine 2.0
Clear Search sequence regions

  • activity (2)
  • cyclic (2)
  • disease parkinson (2)
  • email (1)
  • GSK 3 (1)
  • intracellular (1)
  • PDE (1)
  • PDE4 (1)
  • PDE7 (11)
  • PDE8 (1)
  • phosphodiesterases (2)
  • research (1)
  • Sizes of these terms reflect their relevance to your search.

    Phosphodiesterase 7 (PDE7) is an intracellular enzyme that specifically hydrolyzes the second messenger, cyclic-3',5'-adenosine monophosphate (cAMP), into inactive noncyclic nucleotide, 5'-AMP. To date, many structurally diverse compounds with PDE7 inhibitory properties have been described, including selective PDE7 inhibitors, dual PDE4/PDE7, PDE7/PDE8, and PDE7/GSK-3 inhibitors, and non-selective PDE inhibitors with high affinity for PDE7. Inhibitors of PDE7 have provided beneficial effects in animal models of inflammatory and neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and many others. This review is a comprehensive summary of the current state-of-the-art in the field of design and synthesis of PDE7 inhibitors, their physicochemical properties, biological evaluation, and structure-activity relationships as well as it highlights the updated evidence for a potential therapeutic utility of these compounds. Moreover, new approaches to obtain more effective and safer PDE7 inhibitors than those available now are presented. Copyright© Bentham Science Publishers; For any queries, please email at


    Agnieszka Jankowska, Artur Swierczek, Grazyna Chlon-Rzepa, Maciej Pawlowski, Elzbieta Wyska. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. Current medicinal chemistry. 2017;24(7):673-700

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 28093982

    View Full Text